SOSV is a global venture capital firm founded in 1995 and headquartered in Princeton, New Jersey. Specializing in seed-to-growth stage investments, SOSV operates multiple accelerator programs worldwide, including HAX for hardware, IndieBio and RebelBio for life sciences, Chinaccelerator and MOX for cross-border internet ventures, Food-X for innovative food solutions, and dlab for blockchain technology. The firm focuses on investments in revolutionary deep technologies aimed at improving human and planetary health, as well as cross-border markets, particularly in Asia. SOSV invests in approximately 150 startups annually, providing support through its resources to accelerate product development and scaling. Over its two-decade history, SOSV has established a strong reputation, consistently ranking among the top venture capital firms globally.

OrbiMed Advisors LLC is a healthcare-focused investment firm founded in 1989, managing approximately $5 billion in assets. The firm specializes in a range of investment strategies, including private equity, venture capital, and public equity, targeting companies across the healthcare spectrum—from startups to large multinational corporations. OrbiMed invests in various sectors within the healthcare industry, including pharmaceuticals, biotechnology, life sciences, medical devices, and health IT. The firm typically invests between $3 million and $150 million, often seeking majority stakes in its portfolio companies. With a global investment approach, OrbiMed operates from offices in New York, San Francisco, Mumbai, Herzliya, Shanghai, West Kowloon, and Luxembourg, focusing on opportunities in North America, Europe, Asia, and Israel. Its investment strategies are underpinned by fundamental analysis, encompassing investments in public equity, fixed income, and alternative markets.

RA Capital Management, L.P. is a Boston-based venture capital firm focused on growth capital and early-stage investments in the healthcare and life sciences sectors. Established in 2001, the firm specializes in funding companies involved in drug development, medical devices, diagnostics, and biotechnology. It engages in a range of investment stages, from seed funding to later rounds and public offerings, often preferring to co-invest and take board positions. RA Capital targets companies that are innovating in areas such as prevention, cost-effective diagnostics, genetic testing, and personalized medicine. The firm is staffed by professionals with backgrounds in biology, chemistry, and medicine, providing them with a deep understanding of the scientific and regulatory landscape. This expertise allows RA Capital to identify promising technologies and offer strategic guidance, including potential partnerships and insights into public market demands.

ARCH Venture Partners, L.P. is a private equity and venture capital firm founded in 1986 and based in Chicago, Illinois, with additional offices across North America and South America. The firm specializes in early-stage and growth capital investments, primarily focusing on life sciences and biotechnology, but also covering a wide array of technology sectors such as advanced materials, communications technologies, and information technology. ARCH is recognized for its role in commercializing innovations developed at academic research institutions and national laboratories. It has raised over $3 billion through ten venture funds and has invested in more than 150 companies, often co-founding them with leading scientists and entrepreneurs. The firm typically invests between $50,000 and $150 million per company, aiming to enter at seed rounds to minimize risk, and seeks a seat on the Board of Directors for its portfolio companies. While primarily investing in the United States, ARCH also targets opportunities in Canada, Europe, and select countries in Asia, focusing on underserved geographic markets rich in scientific research and technological talent.

The Bill & Melinda Gates Foundation is a prominent grant-making organization co-founded by Bill and Melinda Gates in 2000, headquartered in Seattle, Washington, with additional offices in Washington, D.C.; New Delhi, India; Beijing, China; and London, United Kingdom. The foundation focuses on improving global health, enhancing education, and providing support to at-risk families, particularly in the Pacific Northwest. It actively promotes strategies that assist low-income families and works towards greater equality in various sectors. The foundation is also involved in investment management, overseeing an endowment that includes a diverse portfolio primarily in public equity and fixed income markets, while excluding tobacco-related investments. Its trustees include Bill Gates, Melinda Gates, and Warren Buffett.

Invus Financial Advisors, LLC is an employee-owned hedge fund sponsor based in New York, specializing in investments across various stages including special situations, venture capital, and growth equity. Founded in 2006, the firm manages over $4 billion in an evergreen fund and operates additional offices in London, Paris, and Hong Kong. Invus focuses on making minority investments and often acts as a lead investor or part of a consortium, emphasizing a flexible approach tailored to the unique needs of each company. The firm has a long-standing commitment to empowering owner-managers, aligning its incentives with those of its partners, and recognizing that meaningful business transformation requires time and resilience. With a history of reinvesting capital from European families since its inception, Invus demonstrates a dedication to fostering long-term relationships and navigating challenges in pursuit of extraordinary performance.

Novo Holdings, established in 1999, is the holding company of the Novo Group, primarily managing the investment assets of the Novo Nordisk Foundation. Based in Copenhagen, with additional offices in San Francisco and Boston, Novo Holdings focuses on two main investment categories: Life Science Investments, which encompasses funding life science companies at various stages of development, and Financial Investments, which entails managing a diversified portfolio of equity and fixed income securities. As a prominent life science investor, Novo Holdings aims to create long-term value while ensuring that the Foundation can distribute returns for scientific, social, and humanitarian purposes to enhance public health and welfare. The company has also developed initiatives such as Novo Seeds, which supports early-stage applied research in life sciences, and invests in later-stage life science companies through growth equity. Novo Holdings maintains a strategic influence over affiliated companies, aligning their operations with the values and objectives of the Novo Group.

Qiming Venture Partners is a prominent venture capital firm established in 2006 and headquartered in Shanghai, with additional offices in Beijing, Suzhou, and Hong Kong. The firm specializes in investing in early to growth-stage companies across various sectors, including media and internet, information technology, consumer and retail, healthcare, and clean technology in China. Since its inception, Qiming has built a reputation as a leading investment firm in the region, managing multiple funds with over $1 billion in assets. The firm aims to support promising entrepreneurs and innovative businesses, contributing to the development of China's dynamic economic landscape.

Casdin Capital, LLC is an investment firm specializing in the life sciences and healthcare sectors. Founded in 2012 by Eli Casdin, who serves as the Chief Investment Officer, the firm employs a fundamental research approach to manage a long-short equity fund. Casdin Capital invests across a spectrum of opportunities, ranging from early-stage to late-stage private investments. As of October 2020, the firm manages approximately $2.2 billion in assets.

Northpond Ventures is a venture capital firm based in Bethesda, Maryland, with additional offices in San Francisco and Cambridge. Founded in 2018, the firm specializes in growth capital investments across various sectors, including life sciences, biotechnology, diagnostics, digital health, and emerging technologies. Northpond Ventures aims to support innovative companies that are poised to make significant advancements in healthcare and technology, with a focus on building a better future through its strategic investments. As a Registered Investment Adviser, the firm is committed to fostering developments in therapeutics, artificial intelligence, machine learning, and medical technology.

Khosla Ventures is a venture capital firm established in 2004 by Vinod Khosla, a co-founder of Sun Microsystems. Based in Menlo Park, California, the firm manages over $5 billion and primarily invests in early-stage technology companies throughout the United States. Khosla Ventures provides capital, strategic advice, and venture assistance to entrepreneurs focused on breakthrough innovations across various sectors, including consumer technology, enterprise solutions, health, education, agriculture, and sustainable energy. The firm has a particular interest in high-risk, high-reward opportunities, often acting as a sole investor in "science or innovation experiments." Investment sizes typically range from $100,000 to over $20 million, allowing Khosla Ventures to support both traditional ventures and unconventional projects.

Perceptive Advisors LLC is an investment management firm founded in 1999 and headquartered in New York City, with an additional office in Boston. The firm specializes in the healthcare sector, focusing on biotechnology, pharmaceuticals, life sciences, diagnostics, digital health, medical devices, and healthcare services. It engages in venture capital and incubation, investing at various stages of a company's life cycle, including seed and Series A funding, as well as late-stage venture and public market investments. Perceptive Advisors employs a long/short equity strategy and utilizes hedging techniques, including equity options and index options, while conducting in-house research to inform investment decisions. The firm also manages separate client-focused equity portfolios and provides customized debt financing solutions through its Perceptive Credit Opportunities Fund. Its clientele includes institutional investors, financial institutions, investment funds, and high-net-worth individuals.

Alexandria Venture Investments, LLC is a venture capital firm established in 1996 and headquartered in Pasadena, California. As the strategic investment arm of Alexandria Real Estate Equities, it focuses on providing capital to seed, early-stage, and growth-stage companies within the healthcare sector. The firm emphasizes investments in biopharma, diagnostics, life sciences, research tools, agrifoodtech, and agtech. Alexandria Venture Investments aims to support innovative entities developing breakthrough technologies and therapies, leveraging its extensive industry knowledge and relationships with leading investors. Its approach is characterized by a commitment to fostering innovation and entrepreneurship in the life sciences and technology sectors.

Samsara BioCapital LLC is a private equity firm established in 2016 and located in Palo Alto, California. The firm specializes in investing in biotechnology companies across the United States, providing capital and strategic support to help advance innovations in the life sciences sector. Samsara BioCapital aims to identify and cultivate promising biotechnological advancements that can transform healthcare and improve patient outcomes.

Wellington Management Company LLP, founded in 1928 and headquartered in Boston, Massachusetts, is a prominent investment management firm providing comprehensive solutions to institutional clients worldwide. The firm specializes in a diverse range of investment strategies, including equity, fixed income, multi-asset, and alternative investments, tailored to meet the unique return and risk objectives of its clients. Wellington Management employs a collaborative approach, leveraging proprietary research and analytical tools to identify opportunities and manage risks across global capital markets. The firm caters to a wide array of clients, including sovereign institutions, endowments, foundations, wealth managers, and insurance companies, spanning more than 50 countries. With a focus on long-term investment principles, Wellington Management fosters independent thought and debate within its teams, ensuring that resources are effectively utilized to deliver consistent results. The firm also emphasizes environmental, social, and governance (ESG) considerations in its research and investment processes, engaging with companies on key ESG topics.

The Redmile Group, established in 2007 and based in San Francisco with an additional office in New York, is a private equity firm specializing in venture capital investments within the healthcare sector. The firm manages multiple funds, including Redmile Biopharma Investments II and III, which focus specifically on the biopharma industry. Redmile Group aims to identify and support innovative healthcare companies, leveraging its expertise to foster growth and development in this critical field.

Bpifrance Financement S.A. is a French financial institution that provides a range of financing solutions and support services aimed at fostering the growth of startups, small and medium-sized enterprises (SMEs), and mid-cap companies. It offers various financial products, including medium to long-term loans, export insurance, and leasing options for both tangible and intangible assets. Additionally, Bpifrance supports companies through consulting services, guarantees for bank financing, and training for executives. The organization also engages in direct investments and manages funds aimed at enhancing the financial landscape for businesses at different stages of their development. Established in 1980 and based in Maisons-Alfort, France, Bpifrance was formerly known as OSEO S.A. and rebranded in July 2013. It operates as a subsidiary of Bpifrance SA, reinforcing its commitment to bolstering the French economy through diversified financial solutions.

Sequoia Capital is a prominent venture capital firm founded in 1972 and based in Menlo Park, California. The firm specializes in investing across various stages of startups, including seed, early, and growth stages, and focuses on sectors such as technology, healthcare, financial services, internet, and mobile. Sequoia typically invests between $100,000 and $1 million in seed companies, $1 million to $10 million in early-stage ventures, and $10 million to $100 million in growth investments. The firm operates globally, with significant activities in regions like Israel, China, and India, where it partners with dynamic founders to build successful companies. Sequoia's extensive portfolio includes notable firms and offers valuable insights and resources, benefiting from decades of experience in the venture capital landscape.

Fidelity Investments is a privately owned investment manager based in Boston, Massachusetts, founded in 1946. The firm offers a wide range of financial services, including individual retirement accounts, 401(k) rollovers, annuities, discount brokerage, and wealth management. It serves a diverse clientele, including individual investors, businesses, financial advisors, and institutions. Fidelity manages equity, fixed income, and balanced mutual funds, investing in public equity and fixed income markets worldwide. The firm conducts in-house research to guide its investment decisions and supports over 32 million clients in achieving their financial goals. Additionally, Fidelity assists more than 22,000 businesses with employee benefit programs and collaborates with over 13,000 financial institutions to provide innovative investment and technology solutions.

Janus Henderson Group plc is a global asset management firm based in London, with additional offices in Jersey and Sydney. Founded in 1934, the company provides a range of investment services to institutional, retail, and high net worth clients. It manages client-focused equity and fixed income portfolios, as well as equity, fixed income, and balanced mutual funds. The firm invests in public equity and fixed income markets, along with real estate and private equity opportunities. As of March 2018, Janus Henderson manages approximately £265.3 billion in assets and employs over 2,000 staff worldwide, dedicated to helping clients achieve their long-term financial objectives.

5AM Ventures is a venture capital firm founded in 2002 and headquartered in San Francisco, California, with an additional office in Boston. The firm specializes in seed- and early-stage investments, focusing on companies within the life sciences, healthcare, and technology sectors. Its investment portfolio includes firms involved in biopharmaceuticals, medical technology, drug delivery technologies, and research instruments. 5AM Ventures is recognized for its commitment to fostering innovation in advanced life science technologies.

Seventure Partners is a Paris-based venture capital firm founded in 1997, specializing in investments in life sciences and information and communication technology. With offices in Munich, Geneva, London, and Basel, the firm manages approximately €660 million and focuses on identifying and nurturing innovative companies with high growth potential across North America, Europe, Asia-Pacific, the Middle East, and Africa. Seventure Partners engages closely with entrepreneurs, leveraging its expertise and extensive networks to support the development of emerging European leaders in their respective fields. The firm employs a team of over 20 professionals, including 15 investors, who possess significant knowledge in technology and private equity operations. Seventure’s investment strategy encompasses various sectors, including TMT, industrial, healthcare devices, and supply, with a typical investment range of €0.5 million to €2 million over a six-year horizon.

T. Rowe Price is a publicly owned investment management firm founded in 1937 and headquartered in Baltimore, Maryland. The company serves a diverse clientele that includes individuals, institutional investors, retirement plans, and financial intermediaries. T. Rowe Price offers a wide array of investment strategies encompassing equity, fixed income, and private equity, with a particular focus on funding technology startups. The firm employs a combination of fundamental and quantitative analysis to guide its investment decisions, utilizing both in-house and external research. Additionally, T. Rowe Price is committed to socially responsible investing, prioritizing environmental, social, and governance factors. With a global presence, the firm operates offices in numerous locations worldwide, enhancing its ability to navigate various markets and deliver reliable investment solutions.

Lilly Asia Ventures, established in 2008 and based in Shanghai, China, serves as the corporate venture capital arm of Eli Lilly and Company. The firm focuses on making investments in the life sciences and healthcare sectors, primarily targeting opportunities in China but also considering ventures in other parts of East and South Asia. Lilly Asia Ventures seeks to invest in companies at various stages, from seed to later stages, with a preference for those showcasing strong management teams and innovative technologies or business models. The investment strategy emphasizes human therapeutics, medical technology, healthcare services, and broader life sciences. Typically, investments range from $5 million to $15 million per round, with an inclination towards acquiring minority stakes, usually under 20 percent. The firm aims to play an active role in its portfolio companies by seeking board seats or observation rights.

Pfizer is one of the largest pharmaceutical companies in the world, founded in 1849 and headquartered in the United States. The company is dedicated to improving health and well-being by applying scientific advancements and global resources. Pfizer manufactures and sells a diverse range of healthcare products, primarily focusing on prescription drugs and vaccines, which account for the majority of its sales. Notable products include the pneumococcal vaccine Prevnar 13, the cancer treatment Ibrance, and the cardiovascular drug Eliquis. With annual sales nearing $50 billion, Pfizer has a strong international presence, with nearly half of its sales derived from global markets, particularly emerging economies. The firm is committed to providing access to safe, effective, and affordable medicines to enhance patient outcomes and address pressing healthcare challenges.

Lux Capital Management is a research-driven investment firm based in New York City and Silicon Valley, specializing in founding, seed, early-stage, and growth investments in the physical and life sciences. The firm actively collaborates with entrepreneurs to build successful businesses in high-growth sectors, having created over 20 companies from inception. Lux invests in a diverse range of industries, including 3D printing, artificial intelligence, flying and surgical robots, synthetic biology, genomics, satellites, drones, and computational imaging. With a focus on providing portfolio companies with better connections and deeper insights, Lux Capital aims to accelerate their industry leadership and competitive advantage. The firm manages approximately $4 billion in assets, reflecting its commitment to fostering innovation and growth in emerging technologies.

Logos Capital is an equity hedge fund manager based in San Francisco, California, founded in March 2019. The firm specializes in fundamental biotechnology investments, leveraging both in-house data analytics and scientific expertise to identify transformative therapies in healthcare. By combining medical, scientific, and statistical disciplines, Logos enhances its investment diligence to uncover compelling opportunities with uncorrelated market returns. The firm's approach integrates statistical modeling of clinical trials with rigorous scientific assessment, aiming to achieve high conviction in its investment positions. Logos Capital manages pooled investment vehicles and focuses on public equity markets, employing a blend of internal research and external insights to inform its investment strategies.

GV Management Company, LLC, established in 2009 as the venture capital arm of Alphabet Inc., specializes in investments across various stages, including seed, early, and late-stage funding. Based in Mountain View, California, with additional offices in Boston, New York, Seattle, Cambridge, and London, GV focuses on sectors such as life sciences, healthcare, artificial intelligence, robotics, transportation, cybersecurity, and agriculture. The firm has invested in over 300 companies, aiming to drive innovation and improve lives. GV seeks to make investments of up to $50 million, while offering early-stage startups funding of up to $250,000, typically taking minority stakes in these companies. Through its extensive network, GV provides startups with unique access to technology and talent, enhancing their potential for success.

Scottish Enterprise is Scotland's primary economic development agency, operating as a non-departmental public body under the Scottish Government. Established in 1991 and based in Glasgow, it aims to foster an innovative and productive economy by partnering with both public and private sectors to identify and capitalize on high-value opportunities. The organization supports small and medium-sized enterprises (SMEs) by helping them secure necessary financing, enhancing management capabilities, and facilitating growth. Through its arm, the Scottish Investment Bank, it engages in direct and fund of fund investments, focusing on sectors such as renewable energy, healthcare, technology, and creative industries. It typically invests between £0.01 million and £10 million, utilizing various financial instruments including loans, equity, and mezzanine financing. Scottish Enterprise also collaborates with UK and international investors, including business angels and venture capital groups, to stimulate the funding market in Scotland and enhance the growth potential of Scottish businesses.

Leaps by Bayer is focused on making transformative advancements in the life sciences, particularly within biotechnology, agriculture, and scientific innovation. Established in 2015 and headquartered in Leverkusen, Nordrhein-Westfalen, the firm aims to invest in groundbreaking technologies that have the potential to significantly improve human life. Leaps by Bayer targets high-impact projects that may currently seem unattainable, acknowledging that setbacks and failures are a natural part of pursuing such ambitious goals. Through sustained investments in disruptive biotechnologies, the organization seeks to drive progress that could fundamentally change the world for the better.

Nextech Invest is a venture capital and private equity firm based in Zurich, Switzerland, with a focus on early, mid-stage, and late-stage investments in healthcare and life sciences. Founded in 1998, the firm specializes in oncology, targeting companies that develop cancer drugs and diagnostics. It invests in projects that have demonstrated efficacy in preclinical animal models or possess viable device prototypes. Nextech Invest is particularly interested in interdisciplinary technical and scientific initiatives, including therapies, diagnostics, and medical technologies. The firm typically invests between CHF 1 million and CHF 5 million per financing round and aims for a board position in its portfolio companies. It seeks to exit investments within three years, primarily through trade sales. Nextech Invest considers opportunities globally, with a specific interest in companies based in Africa, the Middle East, Asia, North America, and Europe, including Switzerland and Germany.

Vivo Capital, LLC is a private equity and venture capital firm established in 1996 and headquartered in Palo Alto, California, with additional offices in Asia. The firm specializes in investing in healthcare sectors, including biotechnology, pharmaceuticals, medical devices, and healthcare services, primarily focusing on companies in the United States and East Asia. Vivo Capital manages approximately $5.8 billion in assets and has invested in over 290 public and private companies globally. The firm employs a multi-fund investment strategy, targeting various financing stages from early-stage ventures to public companies, and typically invests between $2 million and $40 million. Vivo Capital's team consists of more than 50 professionals with diverse expertise in medical, scientific, and entrepreneurial fields, allowing the firm to identify and nurture high-quality companies within the healthcare industry.

SR One is the corporate venture capital arm of GlaxoSmithKline, focused on investing in emerging life science companies worldwide. Since its inception in 1985, SR One has committed approximately 800 million to over 180 companies that are developing innovative scientific solutions aimed at significantly enhancing medical care. The firm seeks to support ventures that are at the forefront of medical advancements, contributing to the evolution of healthcare practices globally.

Eli Lilly and Company, founded in 1876, is a prominent American pharmaceutical firm engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical products. The company operates facilities in the United States, Puerto Rico, and 25 other countries, distributing its products in approximately 135 countries worldwide. Eli Lilly's product portfolio includes treatments for various medical conditions, particularly in the fields of neurosciences and endocrinology. Notable products include Zyprexa for schizophrenia and bipolar disorder, Cymbalta for depression and anxiety, and Humalog for diabetes management. In addition to its pharmaceutical business, Eli Lilly also conducts research aimed at improving animal health and food production efficiency. The Eli Lilly Foundation further supports community initiatives focused on enhancing patient outcomes and educational opportunities, particularly in underserved areas.

Polaris Partners is a venture capital firm founded in 1996 and headquartered in Boston, Massachusetts. With a focus on technology and healthcare sectors, Polaris invests in companies at all stages of development, from inception to profitable growth. The firm has a history of partnering with experienced entrepreneurs and innovators, aiming to enhance the way people live and work. In addition to its Boston headquarters, Polaris has offices in San Francisco and New York, and it actively targets investments in life sciences, biotechnology, and software industries across the United States and Europe. Over its more than two-decade history, Polaris Partners has established itself as a multibillion-dollar investment firm committed to fostering innovation and entrepreneurship.

5Y Capital is a private equity and venture capital firm based in Shanghai, China, specializing in seed, startup, early venture, and growth capital investments. Established in 1992, the firm focuses on a diverse range of sectors, including healthcare, technology, fintech, internet services, consumer services, media, and life sciences, among others. It aims to support entrepreneurs in building innovative companies, particularly in China and other emerging markets in Asia/Pacific. Managing approximately USD 5 billion in dual-currency funds, 5Y Capital attracts investments from global sources, including sovereign wealth funds and family offices. The firm typically makes initial investments exceeding USD 500,000 per portfolio company. 5Y Capital operates under the Morningside Group, which is committed to socially responsible investing, particularly in educational opportunities and scientific research.

EcoR1 Capital, LLC is an employee owned hedge fund sponsor. The firm provides its services to pooled investment vehicles. The firm also manages separate client-focused equity and fixed income portfolios. The firm invests in the public equity markets of the United States. It employs long/short strategy to make its investments. The firm typically invests in companies in biotechnology sector. EcoR1 Capital, LLC was founded in 2012 and is based in San Francisco, California.

Temasek Holdings is an investment company based in Singapore, founded in 1974, with a diverse portfolio valued at approximately S$242 billion. The firm invests across various sectors, including telecommunications, media and technology, financial services, transportation, consumer products, real estate, life sciences, agriculture, and energy. Temasek's investment strategy is guided by long-term trends, focusing on themes such as transforming economies, rising middle-income populations, and emerging champions. Its investment structure includes a mix of liquid assets, listed and unlisted holdings, and private equity, reflecting a commitment to being a significant shareholder in both local and international businesses. Temasek Capital Management, a subsidiary, specializes in private equity and mid-stage technology and life sciences investments, further enhancing Temasek's global investment footprint.

Takeda Pharmaceutical Company Limited, founded in 1781 and headquartered in Tokyo, Japan, is a leading research-based pharmaceutical company. It operates primarily in the pharmaceutical sector, focusing on five core therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which contribute to over 80% of its revenue. Takeda's diverse product portfolio includes established medications for conditions such as prostate cancer, peptic ulcers, hypertension, and diabetes. Additionally, Takeda Ventures, Inc., the company's venture capital arm, invests in therapeutic innovations across various stages of development, primarily in the United States, Canada, and Europe. The firm prioritizes investments in drug and biotherapeutic technologies, with a particular interest in cardiometabolic, central nervous system, chronic inflammatory, and oncology domains, while avoiding sectors like diagnostics and anti-infective products. In fiscal 2023, Takeda reported revenue of approximately JPY 4.3 trillion, with a significant portion generated from its operations in the US, Japan, and Europe.

RTW Investments, LP is an employee-owned hedge fund manager based in New York, established in 2009. The firm specializes in a sector-oriented investment strategy, focusing primarily on the life sciences, big data, and digital health sectors in the United States and Europe. RTW Investments manages pooled investment vehicles and also offers separate client-focused equity and fixed income portfolios, including equity mutual funds. The firm emphasizes fundamental research and conducts in-house analyses to inform its investment decisions, aiming to capitalize on opportunities in both public equity and fixed income markets globally.

DCVC, founded in 2010 and based in Palo Alto, California, is a venture capital firm that invests in seed and early-stage companies across various sectors, including artificial intelligence, exascale computing, climate, engineering, materials science, robotics, space, water, biology, defense, security, and deep tech. The firm leverages a unique team of experienced venture capitalists, technology entrepreneurs, and practicing engineers, bringing together over 35 technology executives and experts from prestigious institutions. DCVC also operates a dedicated fund, DCVC Bio, which focuses on early-stage startups in computational biology, aiming to harness advancements in genetic sequencing, artificial intelligence, and automation to drive innovation in synthetic biology, medicine, and agriculture. With a proven track record of over 150 companies and 40 material exits, DCVC is committed to fostering deep technological changes that enhance life sciences and IT infrastructure.

HBM Healthcare Investments is a principal investment firm established in 2001 and based in Zug, Switzerland, with a focus on the biotechnology, human medicine, diagnostics, and medical technology sectors. The firm invests globally in approximately 40 mature emerging companies, primarily targeting private firms that demonstrate significant value creation potential. Approximately two-thirds of its portfolio consists of investments in unquoted companies, while the remainder includes public companies and funds. HBM Healthcare Investments has developed a distinctive market position through its strategic investments in firms whose products are either at advanced stages of development or already available in the market. This diversified approach allows the firm to leverage opportunities across Europe, Asia, and North America, contributing to its broad shareholder base and enhancing its investment capabilities.

Atlas Venture L.P. is a private equity and venture capital firm based in Cambridge, Massachusetts, founded in 1980. The firm specializes in early-stage investments, primarily in the life sciences and technology sectors. In life sciences, Atlas Venture focuses on biotechnology, therapeutics, medical technologies, and personalized medicine. In technology, it targets areas such as fintech, consumer innovation, and emerging web services. The firm employs a seed-led venture creation strategy that emphasizes rigorous selection of promising startups led by capable entrepreneurs. Atlas Venture typically invests between $500,000 and $5 million in its portfolio companies, often taking the lead role and seeking board representation. The firm manages over $2 billion in committed capital and has been involved with more than 350 companies across various countries. Its investment strategy prioritizes opportunities in the United States, particularly in regions such as New England and California.

S2G Ventures, established in 2014 and based in Chicago, is a multi-stage venture fund focused on food and agriculture. The firm aims to support entrepreneurs whose products and services address the growing consumer demand for healthy, sustainable, and local food options. S2G Ventures identifies various sectors within the food system that are poised for transformation and builds a diverse portfolio through seed, venture, and growth-stage investments. Its investment areas encompass agriculture, food ingredients, infrastructure and logistics, food safety and technology, as well as retail, restaurants, and consumer brands. The firm’s mission is to drive innovation in these sectors to enhance sustainability and health in the food supply chain.

Third Rock Ventures, LLC is a venture capital firm founded in 2007 and based in Boston, Massachusetts, with an additional office in San Francisco, California. The firm specializes in startup and early-stage investments primarily in life sciences, focusing on biotechnology, medical technology, therapeutics, oncology research, and cardiovascular medical devices. Third Rock Ventures targets transformational companies that demonstrate high growth potential and aims to make initial investments of up to $35 million. The firm typically leads investment rounds and actively engages in its portfolio companies, often taking on key management roles. It seeks collaborations with larger pharmaceutical and biotechnology firms to enhance the development of its investments.

F Prime, Inc. is a venture capital firm based in Cambridge, Massachusetts, with additional offices in San Francisco and London. Founded in 1969, it is part of the legacy of Fidelity Investments, one of the largest asset management firms in the world. F Prime focuses on investing in North American and European companies across various sectors, including healthcare, life sciences, medtech, technology, and health information technology. The firm operates several specialized funds, such as those dedicated to healthcare and life sciences, which aim to support early-stage companies in these industries. With a commitment to fostering entrepreneurship, F Prime leverages its extensive insights, domain expertise, and relationships to assist entrepreneurs in building impactful companies, all while avoiding the pressures of external fundraising.

Omega Funds is a Boston-based private equity firm established in 2004, specializing in early-stage investments in healthcare and biotechnology companies across North America and Western Europe. The firm offers investors the opportunity to diversify their portfolios and enhance return potential, leveraging the expertise of institutional portfolio managers. With a minimum investment requirement of $500, Omega Funds aims to make sophisticated investment strategies accessible to a broader range of investors.

Matrix Partners is a venture capital firm established in 1977, with offices in San Francisco, Cambridge, Shanghai, Beijing, Mumbai, and Bangalore. The firm focuses on seed, early-stage, late-stage, and growth capital investments across various sectors, including software, communications, artificial intelligence, fintech, digital health, and clean technology. With a commitment to building long-term relationships with entrepreneurs, Matrix Partners aims to support visionary founders in developing significant, industry-leading companies. The firm has a strong track record, having participated in hundreds of investments, with many of its portfolio companies achieving successful IPOs or profitable mergers and acquisitions. The team at Matrix Partners combines local insights with global expertise, comprising both former entrepreneurs and seasoned investors.

Illumina Ventures is a California-based venture capital firm founded in 2016, specializing in early-stage investments in the life sciences and healthcare sectors. The firm operates as an independently managed fund in strategic partnership with Illumina, which provides significant capital and access to its expertise in genomics. Illumina Ventures focuses on investing in companies that are pioneering applications of nucleic acid sequencing and developing innovative products that enhance the genomics ecosystem, including tools, diagnostics, and therapeutics. The firm typically invests between $5 million and $10 million and collaborates with other leading institutional and strategic investors. Its investment areas encompass life science research, healthcare, agriculture, environmental science, public safety, and personal wellness, aiming to leverage genomics to improve human health.

Sofinnova Partners is an independent venture capital firm headquartered in Paris, France, with a focus on the life sciences sector, including biopharmaceuticals, biotechnology, medical devices, and industrial biotechnology. Over its 45-year history, the firm has financed nearly 500 companies, primarily targeting start-ups, early-stage ventures, corporate spin-offs, and occasional turnaround situations. Sofinnova Partners actively sources investment opportunities and often serves as the first institutional investor in Series A financings, taking a lead role in its portfolio companies. The firm engages closely with entrepreneurs from the formation phase, holding board positions and guiding companies through their development until exit. While primarily investing throughout Europe, Sofinnova Partners also allocates a portion of its investments globally.